|Series A, 12/08 |
Flybridge Capital Partners
North Bridge Venture Partners
SpringLeaf Therapeutics, Inc. was formerly known as Entra Pharmaceuticals, Inc. and changed its name to SpringLeaf Therapeutics, Inc. in March 2011. The company was incorporated in 2007 and is based in Boston, Massachusetts.
SpringLeaf Therapeutics is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf’s technology is based on the convergence of materials science and medicine and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Excel Venture Management, Flybridge Capital Partners, North Bridge Venture Partners and SR One.